Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novartis Japan Sees 2023 OK for 1st siRNA Drug for Hyperlipidemia, 7 Approvals to Drive Growth
March 27, 2023
- Takeda Puts Up 100 Billion Yen for New Plasma Therapy Facility in Japan
March 24, 2023
- Ono, Kasawaki-Based AI Platform Firm Tie Up on Antibody Drug Discovery
March 24, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Ono, Macomics Ink Macrophage Drug Discovery Deal
March 24, 2023
- Opdivo Gets South Korea OK for 1st Line Esophageal Cancer
March 24, 2023
- Detailed Data Out for PIII Zolbetuximab Study in 1st-Line Gastric Cancer: Astellas
March 23, 2023
- Kowa Launches Global PIII for Ripasudil for Fuchs Endothelial Corneal Dystrophy
March 23, 2023
- Senju Starts Japan PIII for Dry Eye Med; Takeda to Be Distributor If Approved
March 23, 2023
- Kobayashi Kako to Withdraw Marketing License on April 1
March 23, 2023
- Pfizer Japan Starts Commercial Rollout of COVID-19 Pill Paxlovid
March 23, 2023
- Opdivo-Yervoy Combo Approved for HCC in Taiwan
March 23, 2023
- Eisai Publishes Updated Social Value Simulation for Lecanemab
March 22, 2023
- Daiichi Sankyo Rolls Out Lung, Breast Cancer Data for HER3-Directed ADC
March 22, 2023
- Mitsubishi Tanabe Files Canaglu OD Tablet Form in Japan
March 22, 2023
- Xtandi Plus Leuprolide Meet PIII Goal in Non-Metastatic Prostate Cancer: Astellas
March 20, 2023
- Takeda Updates Qdenga Peak Sales Estimate to US$1.6-2 Billion
March 17, 2023
- Fujifilm to Make Foray into Drug Discovery CRO Business
March 17, 2023
- Twymeeg No 1 in GP Promotion in January, Dayvigo Most Pitched for HP: Intage
March 17, 2023
- CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…